Mariner
PTGX icon

Mariner’s Protagonist Therapeutics PTGX Stock Holding History

Mariner’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$292K Sell
2,775
-4,845
-64% -$429K ﹤0.01% 2903
2025
Q4 		$666K Sell
7,620
-5,931
-44% -$485K ﹤0.01% 2249
2025
Q3 		$900K Sell
13,551
-2,150
-14% -$122K ﹤0.01% 1997
2025
Q2 		$868K Sell
15,701
-930
-6% -$44.6K ﹤0.01% 1901
2025
Q1 		$804K Sell
16,631
-1,352
-8% -$56.7K ﹤0.01% 1839
2024
Q4 		$694K Buy
17,983
+2,004
+13% +$87.4K ﹤0.01% 1912
2024
Q3 		$719K Buy
15,979
+3,696
+30% +$149K ﹤0.01% 1859
2024
Q2 		$426K Sell
12,283
-441
-3% -$12.9K ﹤0.01% 2167
2024
Q1 		$368K Buy
12,724
+3,470
+37% +$94.4K ﹤0.01% 2268
2023
Q4 		$212K Sell
9,254
-5,288
-36% -$92.5K ﹤0.01% 2647
2023
Q3 		$243K Buy
14,542
+3,708
+34% +$72K ﹤0.01% 2345
2023
Q2 		$299K Sell
10,834
-3,238
-23% -$81K ﹤0.01% 2119
2023
Q1 		$324K Buy
14,072
+3,423
+32% +$57.5K ﹤0.01% 2008
2022
Q4 		$116K Sell
10,649
-2,458
-19% -$20.7K ﹤0.01% 2488
2022
Q3 		$110K Buy
+13,107
New +$124K ﹤0.01% 2184

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Mariner's PTGX Position: Q1 2026 in Review

Mariner reduced its Protagonist Therapeutics (PTGX) stake by 64% in Q1 2026, selling an estimated $429K and leaving 2,775 shares worth $292K. The position accounts for ﹤0.01% of the portfolio, ranked #2903.

Mariner first reported a position in PTGX in Q3 2022 and has held it in 15 quarters since. The position peaked at $900K in Q3 2025. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • Mariner held 2,775 shares of Protagonist Therapeutics worth $292K as of Q1 2026.
  • Mariner sold 4,845 Protagonist Therapeutics shares in Q1 2026, an estimated $429K.
  • Protagonist Therapeutics made up ﹤0.01% of Mariner's portfolio in Q1 2026, its #2903 holding.
  • Mariner first reported a position in Protagonist Therapeutics in Q3 2022 and has held it in 15 quarters since.
  • Mariner's Protagonist Therapeutics position peaked at $900K in Q3 2025.
  • 317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Mariner's 13F filing for Q1 2026, filed 13 May 2026.